Fracture Prevention with Vitamin D Supplementation: a Meta-analysis of Randomized Controlled Trials
Overview
Authors
Affiliations
Context: The role and dose of oral vitamin D supplementation in nonvertebral fracture prevention have not been well established.
Objective: To estimate the effectiveness of vitamin D supplementation in preventing hip and nonvertebral fractures in older persons.
Data Sources: A systematic review of English and non-English articles using MEDLINE and the Cochrane Controlled Trials Register (1960-2005), and EMBASE (1991-2005). Additional studies were identified by contacting clinical experts and searching bibliographies and abstracts presented at the American Society for Bone and Mineral Research (1995-2004). Search terms included randomized controlled trial (RCT), controlled clinical trial, random allocation, double-blind method, cholecalciferol, ergocalciferol, 25-hydroxyvitamin D, fractures, humans, elderly, falls, and bone density.
Study Selection: Only double-blind RCTs of oral vitamin D supplementation (cholecalciferol, ergocalciferol) with or without calcium supplementation vs calcium supplementation or placebo in older persons (> or =60 years) that examined hip or nonvertebral fractures were included.
Data Extraction: Independent extraction of articles by 2 authors using predefined data fields, including study quality indicators.
Data Synthesis: All pooled analyses were based on random-effects models. Five RCTs for hip fracture (n = 9294) and 7 RCTs for nonvertebral fracture risk (n = 9820) met our inclusion criteria. All trials used cholecalciferol. Heterogeneity among studies for both hip and nonvertebral fracture prevention was observed, which disappeared after pooling RCTs with low-dose (400 IU/d) and higher-dose vitamin D (700-800 IU/d), separately. A vitamin D dose of 700 to 800 IU/d reduced the relative risk (RR) of hip fracture by 26% (3 RCTs with 5572 persons; pooled RR, 0.74; 95% confidence interval [CI], 0.61-0.88) and any nonvertebral fracture by 23% (5 RCTs with 6098 persons; pooled RR, 0.77; 95% CI, 0.68-0.87) vs calcium or placebo. No significant benefit was observed for RCTs with 400 IU/d vitamin D (2 RCTs with 3722 persons; pooled RR for hip fracture, 1.15; 95% CI, 0.88-1.50; and pooled RR for any nonvertebral fracture, 1.03; 95% CI, 0.86-1.24).
Conclusions: Oral vitamin D supplementation between 700 to 800 IU/d appears to reduce the risk of hip and any nonvertebral fractures in ambulatory or institutionalized elderly persons. An oral vitamin D dose of 400 IU/d is not sufficient for fracture prevention.
Migliorini F, Maffulli N, Colarossi G, Filippelli A, Memminger M, Conti V Eur J Med Res. 2025; 30(1):170.
PMID: 40087804 DOI: 10.1186/s40001-025-02412-x.
Expert consensus on vitamin D in osteoporosis.
Lei S, Zhang X, Song L, Wen J, Zhang Z, Tian J Ann Jt. 2025; 10:1.
PMID: 39981430 PMC: 11836767. DOI: 10.21037/aoj-24-48.
Vitamin D deficiency in hip fracture patients is associated with an increased mortality risk.
Bayram J, Kanesan H, Clement N Eur J Orthop Surg Traumatol. 2024; 35(1):33.
PMID: 39621172 PMC: 11611993. DOI: 10.1007/s00590-024-04162-8.
Alijanpour K, Afzal S, Alijanpour A, Barati H, Gholinia H, Tavassoli M PLoS One. 2024; 19(11):e0313023.
PMID: 39576768 PMC: 11584120. DOI: 10.1371/journal.pone.0313023.
The Prevalence of Low Vitamin D in Elite Para-Athletes: A Systematic Review.
Langley C, Morse C, Buffey A Sports Med Open. 2024; 10(1):96.
PMID: 39230661 PMC: 11374943. DOI: 10.1186/s40798-024-00756-y.